Breast Cancer Intravoxel-incoherent-motion MRI Multisite (BRIMM) Study - Resubmission - 1

项目总结 虽然磁共振成像(MRI)的技术事业产生了一系列的生物标志物 肿瘤环境，尤其是乳腺癌，极少数(通常只有一阶标记物)有 在单一工作流程处理的单一现场研究之外进行了测试。要同时满足对高级 组织特征和多部位翻译，我们提出了一项体素内非相干运动的多部位研究 (IVIM)MRI在乳腺癌中的应用，以确定其最大的转化预后益处。IVIM模型，它 包括组织细胞密度、血管体积和微血管流量的单独标记，已经成功 应用于包括乳腺癌在内的一系列癌症的项目团队提出了这一建议。这个项目将 确定技术随硬件变化(3个供应商)和软件平台(6个)的内在变异性 包)，对5个部位的临床乳腺癌IVIM资料进行回顾性分析。然后我们将进行一次 接受新辅助化疗患者的前瞻性两点静脉注射纵向研究 预测治疗反应的最佳治疗前或治疗中期生物标志物。在每个阶段，表演将是 在每个地点和组合队列中进行评估，目标是确定既是 有用且可广泛翻译。

PROJECT SUMMARY While the technological enterprise of magnetic resonance imaging (MRI) generates a host of biomarkers of the tumor environment, in particular for breast cancer, precious few (and typically only first-order markers) have been tested beyond single site studies with single workflow processing. To address both the need for advanced tissue characterization and multi-site translation, we propose a multi-site study of intravoxel incoherent motion (IVIM) MRI in breast cancer to determine its maximum translational prognostic benefit. The IVIM model, which includes separate markers of tissue cellularity, vascular volume, and micro-vascular flow, has been successfully applied in a range of cancers, including breast cancer by the project teams of this proposal. This project will determine inherent variability of the technique with hardware variation (3 vendors) and software platforms (6 packages), in a 5 site retrospective analysis of clinical breast cancer IVIM data. We will then conduct a prospective two-site IVIM longitudinal study of patients undergoing neoadjuvant chemotherapy to determine the best pre- or mid-treatment biomarkers to predict therapeutic response. At each stage, performance will be evaluated both within each site and in the combined cohort, with the goal of identifying biomarkers that are both useful and broadly translatable.